Atossa Therapeutics, Inc. ATOS 深 沪
已收盘 05-22 16:00:00 美东时间
4.96
-0.010
-0.20%
华盛通- 最 高5.10
- 今 开4.93
- 成交量 2.82万股
- 最 低 4.8383
- 昨 收 4.97
- 总市值 4271.24万
- 52周最高 19.35
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 3.76
- 委 比 -99.21%
- 总股本 861.14万
- 历史最高 33480.00
- 量 比 0.60
- 振 幅 5.27%
- 历史最低 4.8383
- 每 手 1
- 风险率 3.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atossa Therapeutics Announces Acceptance Of (Z)-Endoxifen DMD Manuscript For Publication In Degenerative Neurological And Neuromuscular Disease
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) researchSEATTLE, May 20, 2026 /PRNewswire/ --
05-21 04:49
Atossa Therapeutics一季度GAAP每股亏损1.11美元
临床阶段生物制药公司Atossa Therapeutics公布2026年第一季度财报，GAAP每股亏损1.11美元。由于公司尚无商业化产品，本季度未录得营收...
05-08 22:49
Atossa Therapeutics GAAP EPS of -$1.11
Atossa Therapeutics press release (ATOS): Q1 GAAP EPS of -$1.11. Operating Expenses. Total operating expenses were $9.9 million for the three months ended March 31, 2026, which was an increase of $2.5...
05-08 21:12
Atossa Therapeutics Q1 EPS $(1.11) Misses $(0.94) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.94) by 19.35 percent. This is a 344 percent decrease over losses of $(0.25) per share
05-08 20:53
Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million
Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million Atossa Therapeutics posted a net loss of USD 9.6 million for the quarter ended March 31, 2026, while reporting no revenue. Operating expenses climbed 33.78% to USD 9.9 million, led by a 15% rise in R&D spending to USD 4.78 million. G
05-08 20:32
Atossa Therapeutics Announces FDA Rare Pediatric Disease Designation To (Z)-endoxifen For The Treatment Of McCune-Albright Syndrome In Females
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application,
05-04 20:38
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- A...
05-04 20:30
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
Atossa Therapeutics ( ($ATOS) ) just unveiled an announcement. On April 16, 202...
04-16 21:47
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and lowers the price target from $120 to $24.
04-10 17:36
